Costa Mesa, California (PRWEB) December 14, 2012
WCCT Global, LLC, a contract research organization (CRO) supporting Phase I - IV biopharmaceutical and device development, today announced beginning its tenth year as an industry leader in the design, execution and evaluation of Asian Bridging Trials for the Global Pharmaceutical Industry. Mel Affrime, Pharm. D., Sr. VP, R&D at WCCT Global said, “The possibility that ethnic differences exist in different populations with regard to metabolism and distribution of drugs has been recognized for years. These differences may be expressed as alterations in safety, efficacy and/or dose, or in terms of adverse event profiles in these ethnically diverse populations. These observations ultimately lead to the publication of ICH E-5 Guidance Document”. WCCT Global has carried out over 60 ethnic bridging trials and recruited over 1200 Asian volunteers since 1993. Kenneth Kim, MD, WCCT Global’s CEO said, “WCCT Global will strive to maintain its industry leadership role in this important area of biopharmaceutical research and development”.
More about WCCT Global’s Clinical Pharmacology Services:
WCCT Global is a multi-site global provider of outsourced early drug development services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision; “With compassion for people, we strive to for tomorrow’s therapies to be available today.” truly exemplifies the focus and reason for their cutting edge work. As a drug development partner, WCCT Global partners with domestic and foreign innovator companies who need regulatory, program management, and strategic consulting support from First-in-Man thru the proof of concept stage with an emphasis on overseeing and executing on trials in special disease populations, ethno-bridging volunteers, and cardiac safety studies. To request information about WCCT Global and its services, click here.
WCCT Global website: http://www.wcct.com